142 results on '"Osman, Keren"'
Search Results
2. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma
3. Characterization of Infectious Complications during the Expected Duration of Cytokine Release Syndrome (CRS) in Patients Receiving CAR T Cell Therapy – Are We over-Treating with Anti-Microbials?
4. CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
5. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter
6. Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory solid organ transplant‐related PTLD
7. CAR T cell Therapy for Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplantation: A Safe and Feasible Therapy for An Orphan Disease
8. Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation
9. A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19
10. A Refined Approach to Onboarding CAR-T and Cellular Therapy Products: A Learned Experience
11. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation
12. Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis
13. Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019
14. A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe ARDS From COVID-19.
15. Patient-Reported Outcomes (PROs) in Zuma-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
16. Safety, Efficacy, and Outcomes of CD19 CAR T Cell Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD) in the Real World Setting
17. Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)
18. CD19-Targeted CAR T Cell Therapy for Concomitant Diffuse Large B Cell Lymphoma and Myeloma
19. Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD)
20. Abstract LB027: Tracking and decoding the antigen specificity of peripherally derived T cells that infiltrate into solid tumors in patients treated with an autologous T cell therapy, PRIME IL-15 (RPTR-147)
21. Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis
22. Clinical Program Manager and Nurse Practitioner Specializing in Immune Effector Cell Therapy
23. 184: Mesenchymal Stromal Cell Therapy for Acute Respiratory Distress Syndrome due to COVID-19
24. The Hematologist's Role in Amyloidosis Management: Disease Awareness, Diagnostic Workup, and Practice Patterns
25. 801 PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients
26. A phase I/II study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis.
27. Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study
28. Cytopenias Following CAR-T Cell Therapy - a Single Center Experience
29. A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis
30. Autologous Stem Cell Transplantation for Plasma Cell Disorders
31. 253 - Safety, Efficacy, and Outcomes of CD19 CAR T Cell Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD) in the Real World Setting
32. 234 - Patient-Reported Outcomes (PROs) in Zuma-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
33. Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma.
34. Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis
35. 115 - Clinical Program Manager and Nurse Practitioner Specializing in Immune Effector Cell Therapy
36. Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
37. A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis
38. Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
39. Timing of Influenza Vaccine Response in Patients That Receive Autologous Hematopoietic Cell Transplantation
40. Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis
41. Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
42. Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
43. Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
44. 26 - Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
45. Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study
46. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment
47. Donor Cell Cardiac Myeloid Sarcoma Following Umbilical Cord Transplantation
48. Secondary Graft Failure in Allogeneic Stem Cell Transplantation for Myelofibrosis - a Single Institution Experience
49. Bendamustine-Brentuximab: Bridging to Transplant
50. Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.